323 results on '"Wilking N"'
Search Results
2. EE93 Effects on Health and Costs of Delayed Implementation of the Oncotype DX® Test for Eligible Breast Cancer Patients
3. Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel
4. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective
5. 1346P Diagnosed with non-small cell lung cancer but not treated
6. Insights into cancer surveillance in Central and Eastern Europe, Israel and Turkey
7. 1471P Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
8. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
9. Tamoxifen and megestrol acetate for postmenopausal breast cancer: Diverging effects on liver proteins, androgens, and glucocorticoids
10. 1588MO_PR A comparative study on costs of cancer and access to medicines in Europe
11. p53 expression in breast and endometrium during estrogen and tamoxifen treatment of surgically postmenopausal cynomolgus macaques
12. High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer
13. Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study
14. Reply to ‘Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Annals of Oncology 2007, vol 18, Suppl 3, pp1-75)’ by Michel P Coleman
15. Summary
16. Preface
17. Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer
18. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment
19. Measuring the efficiency of cancer care in Europe
20. Adjuvant Tamoxifen Treatment in Operable Breast Cancer. Should the Treatment Continue for Many Years?
21. Access to cancer drugs in Europe years 2005-2014
22. 13P - Measuring the efficiency of cancer care in Europe
23. Assessing The Esmo Magnitude of Clinical Benefit Scale From A Health Economics Perspective
24. Breast cancer care and outcomes in 18 countries in Europe, Asia, and Latin America
25. A review of breast cancer care and outcomes in 18 countries in Europe, Asia, and Latin America
26. Estradiol formation and estrogen receptors in breast tumor tissue: Effects of tamoxifen on estrogen interconversions in breast tumor homogenate in vitro
27. 1368P - Access to cancer drugs in Europe years 2005-2014
28. Insights into cancer surveillance in C entral and E astern E urope, I srael and T urkey
29. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy.
30. PHP3 A Review of Breast Cancer (BC) Care and Outcomes in Latin America & Caribbean (LAC)
31. Breast cancer (BC) care and outcomes in Latin America and the Caribbean (LAC).
32. Use of oncology drugs in Japan compared to France, Germany, Italy, Spain, Sweden, the United Kingdom, and the United States: A comparison based on data from 1999 to 2009.
33. The burden of cancer in Japan, the United States, France, Germany, Italy, Spain, Sweden, and the United Kingdom.
34. Health-related quality of life during hormone therapy after breast cancer: a randomized trial
35. Abstract P1-09-05: Re-Testing of HER2 Status in Recurring Metastatic Breast Cancer Is a Clinically Relevant and Cost-Effective Strategy
36. Breast cancer patients access to screening, radiotherapy, and cancer drugs in 18 European, Asian, and Latin American countries.
37. 540 Uptake of trastuzumab (T) in selected European countries during the first 9 years after market introduction
38. 508 Breast cancer care and outcomes in 18 countries in Europe, Asia, and Latin America
39. Health Related Quality of Life (HRQoL) in Swedish Relapse Free Breast Cancer Patients. A Study of EQ5D and TTO in a Patient Advocacy Population.
40. Hormone replacement therapy after breast cancer: attitudes of women eligible in a randomized trial
41. The access to oncology drugs in France, Germany, Italy, Spain, and the United Kingdom: A comparison based on data from 1998 to 2007
42. European benchmarking of lung cancer care
43. Uptake of aromatase inhibitors (AI) and trastuzumab (T) during the first 5 years after market introduction. A North American and European comparison
44. Tailored fluorouracil, epirubicin, and cyclophosphamide compared withmarrow-supported high-dose chemotherapy as adjuvant treatment forhigh-risk breast cancer: a randomised trial. Scandinavian Breast G
45. PCN43 COST OF INTRAVENOUS ADMINISTRATION OF BISPHOSPHONATES IN PATIENTS WITH METASTATIC BREAST CANCER
46. Inter- and intra-country variations in the use of trastuzumab in Norway, Spain and Sweden
47. The utilization of new oncology drugs: A global perspective
48. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer (MBC) patients in Sweden
49. HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients
50. Hormone therapy and estrogen receptor expression in breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.